Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 08, 2019 07:00 ET | Source: Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals to Present at Upcoming Investor Conference

THE WOODLANDS, Texas, May 08, 2019 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Lonnel Coats, President and Chief Executive Officer, will present at the...
May 01, 2019 07:00 ET | Source: Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides a Business Update

THE WOODLANDS, Texas, May 01, 2019 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results and provided a business update for the three months ended March...
April 26, 2019 16:01 ET | Source: Lexicon Pharmaceuticals, Inc.; Sanofi

Zynquista™ now Approved in the European Union for Treatment of Adults With Type 1 Diabetes

PARIS and THE WOODLANDS, Texas, April 26, 2019 (GLOBE NEWSWIRE) -- The European Commission has granted marketing authorization for Zynquista™ (sotagliflozin)*, developed by Sanofi and Lexicon...
April 25, 2019 07:00 ET | Source: Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals to Host First Quarter 2019 Financial Results Conference Call and Webcast on May 1, 2019

THE WOODLANDS, Texas, April 25, 2019 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), will release its first quarter 2019 financial results on Wednesday, May 1, 2019 before market...
April 02, 2019 07:00 ET | Source: Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals to Present at Upcoming Investor Conference

THE WOODLANDS, Texas, April 02, 2019 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Lonnel Coats, President and Chief Executive Officer, will present at the...
March 22, 2019 14:16 ET | Source: Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals to Host Conference Call and Webcast Today, March 22, 2019 to Provide a Regulatory Update on Sotagliflozin in Type 1 Diabetes

THE WOODLANDS, Texas, March 22, 2019 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that management will conduct a conference call and live webcast today, Friday,...
March 22, 2019 14:16 ET | Source: Lexicon Pharmaceuticals, Inc.

FDA Issues Complete Response Letter for Zynquista™ (sotagliflozin)

PARIS and THE WOODLANDS, Texas, March 22, 2019 (GLOBE NEWSWIRE) -- The U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) regarding the New Drug Application for...
March 15, 2019 10:39 ET | Source: Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals Announces Dosing of First Patient in TELE-ABC Study, a Phase 2a Clinical Study of Telotristat Ethyl in Biliary Tract Cancer

THE WOODLANDS, Texas, March 15, 2019 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today dosing of the first patient in the Telotristat Ethyl for Advanced Biliary Tract...
March 13, 2019 07:00 ET | Source: Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals Reports Fourth Quarter and Full-Year 2018 Financial Results and Provides a Business Update

XERMELO® (telotristat ethyl) 2018 U.S. Net Sales Reached $25.0 Million Sotagliflozin in Type 1 Diabetes: March 22 PDUFA Date in U.S., European Commission Decision Expected in Q2 2019 Following...
March 11, 2019 16:00 ET | Source: Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals to Host Fourth Quarter and Full-Year 2018 Financial Results Conference Call and Webcast on March 13, 2019

THE WOODLANDS, Texas, March 11, 2019 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), will release its fourth quarter and full-year 2018 financial results on Wednesday, March 13,...